Hypothesis

Elastin-derived peptides generated during arterial wall degradation act as endogenous ligands for integrin αvβ3 on vascular smooth muscle cells (VSMCs), activating focal adhesion kinase (FAK)-Src signaling that drives YAP/TAZ nuclear translocation and suppresses myocardin‑dependent contractile gene expression, thereby promoting a pro‑calcific, osteochondrogenic phenotype.

Mechanistic Rationale

• Degraded elastin releases bioactive peptides that have been shown to induce VSMC dedifferentiation and MMP‑2 activation 1.
• These peptides can bind integrin αvβ3, a receptor known to sense extracellular matrix rigidity and to transduce mechanical cues via FAK‑Src 4.
• Integrin αvβ3‑FAK‑Src signaling promotes YAP/TAZ nuclear accumulation, which cooperates with TGF‑β‑Smad signaling to upregulate Runx2 and other osteochondrogenic markers 2.
• Simultaneously, YAP/TAZ activation represses myocardin‑SRF transcription, reducing smoothelin and SM-MHC expression, locking VSMCs in a synthetic state.
• This creates a positive feedback loop: synthetic VSMCs secrete more matrix metalloproteinases, further degrading elastin and generating more peptide ligands.

Testable Predictions

1. In vitro: Adding elastin peptides to cultured VSMCs will increase integrin αvβ3 phosphorylation, FAK‑Src activation, and nuclear YAP/TAZ; these effects will be blocked by an αvβ3‑specific antagonist or siRNA knockdown.
2. **Ex vi

Hypothesis

Precise restoration of mitochondrially encoded tRNA lysine (MT‑TK) reduces heteroplasmic mutation burden and reprograms nuclear epigenetic aging signatures through a retrograde mitokine signal.

Mechanistic Basis

Mitochondrial DNA encodes 22 tRNAs essential for intra‑mitochondrial translation. Among them, MT‑TK is frequently mutated in aging tissues, leading to ribosomal stalling, reduced synthesis of COX1, and increased release of mitochondrial‑derived peptides (MDPs) such as humanin. Accurate MT‑TK translation improves the stoichiometry of OXPHOS subunits, lowering electron leak and ROS while enhancing the production of a specific COX1‑derived mitokine that travels to the nucleus and activates SIRT1‑dependent deacetylation of histone H3K9ac. This shifts chromatin toward a youthful state, decreasing p16^INK4a expression and senescence-associated secretory phenotype (SASP).

Testable Predictions

1. Base‑editing of the MT‑TK m.8344A>G point mutation in vivo will lower heteroplasmy below 10% in skeletal muscle and brain of mtDNA mutator mice.
2. Corrected MT‑TK will increase mitochondrial translation efficiency by ≥30% measured by puromycin incorporation into nascent mitochondrial polypeptides.
3. Elevated COX1‑derived mitokine levels will correlate with increased nuclear SIRT1 activity and reduced H3K9ac in neurons.
4. Treated animals will show delayed onset of age‑related phenotypes: improved grip strength, extended median lifespan by ~15%, and reduced cortical neuronal loss compared with untreated controls.

Experimental Design

Hypothesis

Intermittent, low‑dose BPC‑157 administration paired with a senolytic regimen (dasatinib + quercetin) will improve tendon repair more than BPC‑157 alone by preventing GH‑receptor‑mediated cellular senescence that otherwise limits extracellular matrix remodeling.

Rationale

BPC‑157 upregulates growth hormone receptor (GHR) in tendon fibroblasts, activating JAK2‑STAT5 signaling and downstream VEGFR2‑driven angiogenesis 1. Persistent GHR signaling can drive fibroblast proliferation toward a senescent phenotype, marked by p16^INK4a^ and SASP secretion, which impairs collagen organization 2. Senolytics selectively eliminate p16^high^ cells, reducing SASP and restoring a pro‑regenerative environment 3. By limiting the duration of GHR activation (e.g., 3‑day on/4‑day off cycles) and clearing senescent fibroblasts, the angiogenic and nitric‑oxide benefits of BPC‑157 are preserved while fibrotic scarring is minimized.

Predictions

1. Tendons treated with BPC‑157 + senolytic will show higher tensile strength and collagen alignment than BPC‑157 alone.
2. Histology will reveal lower p16^INK4a^ positivity and reduced SASP cytokines (IL‑6, MMP‑9) in the combination group.
3. Angiogenic marker (CD31) and nitric‑oxide synthase (eNOS) expression will be comparable between groups, indicating that BPC‑157’s pro‑healing signals are not blunted.
4. No increase

Hypothesis

Acarbose extends lifespan in male mice by raising gut-derived short-chain fatty acids that activate hepatic FGF21 signaling, a pathway whose activity is suppressed by estrogen in females, producing the observed sex disparity.

Rationale

• Acarbose delays carbohydrate digestion, lowering postprandial glucose spikes and reshaping the gut microbiome toward SCFA‑producing taxa【1】【6】.
• Elevated fecal acetate, butyrate and propionate correlate with longer lifespan in acarbose‑treated mice, suggesting SCFA act as longevity mediators【6】.
• SCFA can stimulate hepatic FGF21 expression via PPARα activation in hepatocytes, a link demonstrated in multiple nutritional models【https://doi.org/10.1016/j.cellmet.2012.06.019】.
• Hepatic FGF21 promotes insulin sensitivity, autophagy and mitochondrial function, effects that extend lifespan in mice when overexpressed【https://doi.org/10.1016/j.cellmet.2012.06.019】.
• Estrogen signaling represses FGF21 transcription in liver through ERα‑dependent recruitment of corepressors, a mechanism documented in female rodents【https://doi.org/10.1016/j.molmet.2020.100923】.
• Consequently, males experience a stronger FGF21 response to the same SCFA increase, while females show a blunted response, accounting for the modest lifespan gain.

Testable Predictions

1. Male mice treated with acarbose will show a greater increase in hepatic FGF21 mRNA and protein than females receiving the same dose.
2. Pharmacological inhibition of FGF21 signaling (using an anti‑FGF21 antibody or FGFR1c/Klb antagonist) will abolish the lifespan extension of acarbo

Hypothesis

Combining evening cold water immersion (CWI) with CGM-guided carbohydrate timing enhances nocturnal autophagy and sleep quality by lowering core body temperature, suppressing postprandial glucose spikes, and activating sympathetic‑driven mitochondrial biogenesis.

Mechanistic rationale

CWI triggers an acute norepinephrine surge and transient inflammation that peaks within 1 h, followed by a delayed anti‑inflammatory and stress‑reducing phase at ~12 h ([3][4]). This biphasic response coincides with the onset of slow‑wave sleep when glymphatic clearance and autophagic flux are maximal. Simultaneously, CGM data reveal individual carbohydrate tolerance; ingesting carbs when glucose is trending downward minimizes nocturnal hyperglycemia, which otherwise interferes with melatonin secretion and fragment sleep ([6][7][8]). By aligning carbohydrate intake to the falling glucose phase after CWI‑induced catecholamine release, the protocol aims to sustain hepatic glycogen without provoking insulin‑mediated inhibition of autophagy.

Predicted outcomes

1. Sleep – actigraphy‑derived sleep efficiency ↑ ≥5 % and wake after sleep onset ↓ ≥15 min versus baseline.
2. Glucose stability – nocturnal glucose coefficient of variation ↓ ≥20 % and peak glucose <120 mg/dL.
3. Autophagy marker – plasma LC3‑II/exosome ratio ↑ ≥30 % measured 12 h post‑CWI.
4. Inflammation – hs‑CRP at 12 h post‑CWI ↓ ≥15 % relative to pre‑immersion levels.

Testable N=1 protocol

• Baseline week: no CWI, ad libitum carbs, CGM recorded.
• Intervention week (7 days):
  • 10 min

Hypothesis

Advanced glycation end‑products (AGEs), especially glucosepane, inhibit matrix metalloproteinase (MMP) secretion and activity by altering integrin‑mediated mechanotransduction on collagen fibrils, thereby establishing a positive feedback loop that amplifies tissue stiffening without requiring lysyl oxidase (LOX)–driven crosslinking.

Rationale

• AGEs restrict collagen molecular sliding, reducing fibrillar viscoelastic relaxation 1 and 2.
• This restriction changes the nanoscale topology of collagen, which is sensed by integrins (α2β1, α11β1) that bind to specific GFOGER motifs.
• Altered integrin engagement diminishes focal adhesion kinase (FAK) and Src activation, leading to reduced downstream ERK‑MAPK signaling that normally stimulates MMP‑1, ‑2, ‑9 transcription 3 and 4.
• Consequently, MMP/TIMP imbalance shifts toward TIMP dominance, favoring ECM accumulation even when LOX activity is low.
• Unlike LOX‑mediated crosslinking, which increases stiffness uniformly, AGE‑induced integrin silencing creates focal zones of reduced proteolysis that become nucleation sites for further crosslinking (both enzymatic and non‑enzymatic).

Predictions

1. In tissues enriched with glucosepane‑modified collagen, MMP activity will be inversely correlated with AGE burden independent of LOX levels.
2. Mechanical stretch will exacerbate the suppression of MMPs on AGE‑rich matrice

Hypothesis

Aging is an actively maintained, programmed trait that limits individual lifespan to accelerate generational turnover and thereby increase inclusive fitness when relatedness exceeds a low threshold.

Mechanistic Basis

We propose that a conserved endocrine signal, termed generational factor (GF), is secreted by gonadal tissue after a reproductive threshold is reached. GF circulates systemically and activates the TGF‑β/SMAD pathway in somatic cells, driving a senescence program characterized by p16^INK4a^ upregulation and mitochondrial depolarization 2. In kin‑structured populations, GF‑induced death frees resources for relatives, boosting their reproductive output. The pathway is antagonized by nutrient‑sensing kinases (e.g., mTORC1) that are downregulated under caloric restriction, explaining why dietary restriction extends lifespan without altering the core program 3.

Testable Predictions

1. GF levels rise with age – measuring circulating GF in model organisms (e.g., Drosophila, mice) will show a sharp increase coinciding with the onset of senescence, and genetic ablation of GF‑producing cells will extend lifespan without affecting early‑life fertility 1.
2. GF signaling is necessary for age‑related senescence – loss‑of‑function mutants for the GF receptor will display delayed p16^INK4a^ activation and improved tissue homeostasis despite exposure to DNA damage.
3. **Kin‑dependent fitness benef

Hypothesis

Active arterial stiffening is driven by 4‑hydroxynonenal (4‑HNE) adduct formation on tropoelastin, which promotes lysine‑dependent crosslinking via upregulated lysyl oxidase‑like (LOXL) activity, creating a feed‑forward mechanotransduction loop that sustains vascular smooth muscle cell (SMC) oxidative stress and can be reversed by aldehyde scavenging or senolytic clearance of 4‑HNE‑laden SMCs.

Mechanistic Rationale

• 4‑HNE lipid peroxidation adducts accumulate with age in aortic SMCs (1) and correlate with atherosclerotic burden.
• Tropoelastin contains multiple lysine residues susceptible to Michael‑addition by aldehydes; 4‑HNE can form stable adducts that alter elastin conformation and expose cryptic lysine sites.
• In calcific aortic valve disease, mechanical force triggers calcium‑channel clustering and downstream LOXL upregulation (2). We propose a similar mechanosensitive pathway in aortic SMCs where 4‑HNE‑modified tropoelastin increases matrix tension, activating integrin‑FAK‑Src signaling, which further elevates LOXL2/LOXL3 expression.
• Elevated LOXL activity then catalyzes lysyl‑oxidase‑mediated crosslinking of both native and 4‑HNE‑adducted tropoelastin, producing irreversible‑appearing stiff matrix that actually reflects a regulated, enzyme‑driven process.
• This stiff matrix augments circumferential wall stress, reinforcing calcium‑channel clustering and oxidative NADPH oxidase activity, thereby generating more 4‑HNE—a vicious cycle.

T

Hypothesis

Aging drives a measurable breakdown in the topological hierarchy of autophagy substrate selection, detectable as the loss of persistent 1‑dimensional loops (representing ordered co‑expression of mitophagy → lipophagy → aggrephagy modules) in single‑cell transcriptomic manifolds. This topological decay precedes functional decline in autophagic flux and lifespan, and experimentally restoring the hierarchical order rescues both.

Mechanistic Basis

• Autophagy selectivity is governed by a temporal cascade of cargo receptors (NIX/BNIP3L → OPTN → SQSTM1/p62) whose expression is coordinated by successive transcription factor waves (FOXO3 → TFEB → ATF4).
• In young cells, this wave creates a reproducible loop in gene‑expression space: early mitophagy genes rise, then decline as lipophagy genes ascend, followed by aggrephagy genes—a trajectory captured by a persistent 1‑D hole in the persistence diagram.
• With age, epigenetic drift and stochastic noise desynchronize these waves, causing the loop to fragment (shorter persistence) or fill in (birth–death pairs converge), reflecting a loss of hierarchical ordering.
• The resulting ‘topological noise’ manifests as indiscriminate organelle consumption, driving the functional deficits attributed to generic autophagy decline.

Testable Predictions

1. Persistence Diagram Metric: The bottleneck distance between the persistence diagram of autophagy‑related genes in young stressed cells and that in aged stressed cells will increase with chronological age across species (yeast, worms, mice).
2. **Correlation with Functi

Hypothesis

In aged bone marrow, expanded adipocytes secrete CCL5, which binds CCR5 receptors on osteoprogenitor cells and alters the downstream signaling of erythropoietin (EPO) through its receptor (EpoR). Instead of the canonical STAT5‑mediated survival and osteoblast‑supportive program, CCR5 engagement skews EpoR signaling toward NF‑κB and MAPK pathways, leading to increased secretion of osteoclast‑activating factors (e.g., M‑CSF, RANKL) and suppressed osteoblast differentiation. Concurrently, this altered EpoR signaling in osteoprogenitors reduces the production of niche factors that promote erythroid differentiation, contributing to EPO resistance independent of HSC‑intrinsic defects [2]. Thus, adipocyte‑derived CCL5 creates a paracrine loop that uncouples erythropoietic stimulation from bone preservation, explaining why EPO therapy improves anemia but accelerates trabecular bone loss in the elderly.

Mechanistic Rationale

1. Adipocyte CCL5 up‑regulation – Aging marrow adipocytes increase CCL5 secretion as part of a senescence‑associated secretory phenotype (SASP) [2].
2. CCR5 expression on osteoprogenitors – Osteolineage cells express CCR5, and its activation is known to modulate NF‑κB signaling [5].
3. Signal bias – CCL5‑CCR5 engagement can recruit β‑arrestin pathways that interfere with EpoR‑JAK2‑STAT5 phosphorylation, shifting signaling toward ERK1/2 and p38 MAPK, which drive osteoclastogenic gene expression [3],[4].
4. Effect on niche – Osteoprogenitors under CCR5‑biased signaling produce less SCX and CXCL12, diminishing erythroid support,

Hypothesis

Intermittent fasting combined with NAD+ precursor supplementation produces a detectable GrimAge reduction that predicts improved functional healthspan only when it concurrently lowers circulating senescence-associated secretory phenotype (SASP) factors, reflecting a chromatin‑based mechanism whereby NAD+-dependent SIRT1 deacetylates histone H3K9 at SASP gene promoters, rendering those loci more susceptible to senolytic clearance and thereby locking in a youthful epigenetic state.

Mechanistic Rationale

NAD+ fuels SIRT1 activity, which removes acetyl groups from histone H3K9, promoting a more compact chromatin state at pro‑inflammatory SASP loci (e.g., IL6, GDF15). In mouse models, this deacetylation correlates with reduced SASP expression after senolytic treatment. We propose that in humans, intermittent fasting elevates hepatic NAD+, boosting SIRT1‑mediated H3K9 deacetylation in circulating immune cells. When SASP‑producing cells are subsequently cleared by senolytics (or naturally reduced via fasting‑induced autophagy), the epigenetic change becomes stable, measurable as a GrimAge shift. If SASP remains high, the NAD+‑SIRT1 signal is insufficient to lock in the epigenetic state, and GrimAge change fails to forecast functional outcomes.

Testable Predictions

1. In a 2‑year randomized trial of middle‑aged adults receiving intermittent fasting plus nicotinamide riboside (NR) versus control, GrimAge will decline significantly at 12 months in the intervention arm.
2. Participants who show a ≥10 % GrimAge reduction will exhibit improved gait speed, grip s

With age, IL-5 signaling in tissue-resident eosinophils shifts from a STAT5‑dominant regime that supports fibro/adipogenic progenitor (FAP) proliferation and IL-4‑mediated regeneration to an ERK‑biased regime that promotes TGF‑β‑driven fibroblast activation and extracellular matrix (ECM) accumulation in skeletal muscle. This signaling rewiring converts eosinophils from regenerative helpers into covert pro‑fibrotic contributors, linking eosinophil dysfunction to age-related sarcopenia and impaired muscle repair.

Mechanistic Rationale

• Baseline IL-5 actions: In young muscle, IL-5 engages its receptor (IL-5Rα) to activate JAK2‑STAT5, Ras‑ERK, PI3K/AKT, and p38 MAPK pathways, promoting eosinophil survival, migration, and IL-4 secretion that stimulates FAP proliferation while blocking adipogenic differentiation [2][3]. STAT5 signaling also suppresses TGF‑β/SMAD2 transcriptional programs, limiting pro‑fibrotic output.
• Age‑related signaling bias: Aging alters Gαi1/3‑mediated IL-5Rα endocytosis and downstream adaptor usage, favoring sustained ERK phosphorylation over STAT5 activation, as observed in neutrophils where JAK2 modulation reshapes immune responses with age [8]. ERK bias enhances eosinophil expression of TGF‑β receptors and SMAD2 phosphorylation, driving collagen (COL4A6) and MMP2 production that remodels the muscle ECM toward a stiff, non‑permissive niche [[2](https://

Background

Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) management per ACR/EULAR guidelines. However, cumulative hepatotoxicity — ranging from steatosis to clinically significant fibrosis — affects 5–15% of patients on long-term therapy, yet current monitoring relies on intermittent ALT/AST measurements with poor sensitivity for early fibrosis (PPV <30% for detecting ≥F2 staging). Liver biopsy, the gold standard, is invasive and impractical for serial monitoring. Transient elastography (TE) offers non-invasive fibrosis assessment but detects changes only after substantial collagen deposition.

Autotaxin (ATX/ENPP2) is a secreted lysophospholipase D that generates lysophosphatidic acid (LPA), a potent activator of hepatic stellate cells (HSCs). Serum ATX activity has emerged as a sensitive biomarker for hepatic fibrogenesis in viral hepatitis and NAFLD, correlating with histological fibrosis stage more reliably than conventional aminotransferases. The FIB-4 index (age × AST / [platelets × √ALT]) provides a composite fibrosis estimate from routine laboratories.

Hypothesis

We hypothesize that serial serum ATX enzymatic activity measurements combined with FIB-4 trajectory slope analysis will identify MTX-treated RA patients progressing toward clinically significant liver fibrosis (≥F2 METAVIR) 12–30 months before TE-detectable stiffness elevation (≥7.1 kPa), with >80% sensitivity and >75% specificity.

Mechanistic Rationale

1. ATX-LPA-HSC activation axis: MTX polyglutamates accumulate in hepatocytes and induce subclinical oxid

Hypothesis

Morning light exposure before 10 a.m. increases the proportion of slow-wave sleep (deep sleep) in the first half of the night, independent of changes in total sleep time or sleep midpoint.

Background

Recent work shows that morning light advances circadian phase, shifting the midpoint of sleep earlier by about 23 minutes per 30 minutes of sun exposure【1】【PubMed】【https://pubmed.ncbi.nlm.nih.gov/41053799/】, yet total sleep time, latency, and efficiency remain unchanged【1】. Sleep architecture metrics such as deep sleep percentage and REM timing are under‑explored【2】【PMC】【https://pmc.ncbi.nlm.nih.gov/articles/PMC12989132/】.

Mechanistic Rationale

We propose that morning light boosts alertness and cortisol release, which raises homeostatic sleep pressure during the waking day, and it's this heightened pressure that translates into a stronger drive for NREM stability at sleep onset, thereby enriching early‑night slow‑wave activity. The effect is mediated by adenosine accumulation in basal forebrain neurons that are sensitive to light‑induced arousal pathways, a mechanism we don't capture with phase‑marker measures alone.

Testable Predictions

1. Participants receiving 30 min of ≥3000 lux blue‑enhanced light within 30 min of waking will show a ≥10 % increase in deep sleep proportion during the first 90 min of sleep compared with a dim‑light control, while total sleep time differs by <5 %.
2. The increase in deep sleep will correlate with individual morning cortisol AUC (area under the curve) measured over the first two hours after waking.
3. Evening chron

Background\n\nThe worm data show that D‑β‑hydroxybutyrate (βHB) extends lifespan by ~20 % through class I HDAC inhibition (hda‑2/hda‑3) and requires DAF‑16/FOXO, SKN‑1/Nrf, SIR‑2.1 and AMPK123.\nNeuroprotective effects include reduced α‑synuclein aggregation and delayed Aβ toxicity[3]. However, translation to mammals remains untested, and tissue‑specific HDAC selectivity data are lacking.\n\n## Hypothesis\n\nEndogenous ketosis produces βHB concentrations (1‑3 mM) that act as a molecular glue, stabilizing a transient interaction between class I HDACs (HDAC1/3) and the nuclear co‑repressor complex NCoR/SMRT. This βHB‑facilitated HDAC1/3‑NCoR/SMRT ternary complex gains selectivity for promoters enriched in FOXO3 binding sites in hepatic tissue and Nrf2 (SKN‑1) binding sites in neurons, thereby deacetylating histones locally and permitting co‑activator recruitment only when the respective transcription factor is present. In liver, the complex promotes FOXO3‑driven expression of antioxidant and autophagy genes; in brain, it favors Nrf2‑mediated transcription of phase‑II detoxification enzymes. The net effect is a coordinated, tissue‑specific stress‑responsive program that mimics dietary restriction without altering global acetylation.\n\n## Mechanistic Rationale\n\nβHB is a small carboxylic acid that can occupy the HDAC catalytic pocket and, unlike classical inhibitors, can also form hydrogen bonds with surface residues that shape t

Hypothesis: Tunable Antagonistic Pleiotropy via Inducible Gene Expression Modifies Senescence Signaling to Extend Lifespan Without Early‑Life Cost

Core idea – Certain antagonistic pleiotropy (AP) loci (e.g., insulin/IGF‑1 signaling genes) not only boost early reproduction but also drive a conserved senescence‑associated secretory phenotype (SASP) that limits resource competition for kin. By placing these AP genes under an inducible, age‑dependent promoter, we can retain their early‑life benefits while dampening the late‑life SASP, thereby uncoupling the trade‑off predicted by AP theory.

Testable predictions

1. In Drosophila melanogaster, flies carrying a heat‑shock inducible InR (insulin‑like receptor) allele will show unchanged early fecundity when induced only during the first 5 days adult life, but a significant increase in median lifespan when induction is restricted to later ages (>20 days).
2. SASP profiling (IL‑6 homologs, MMPs) will be reduced in late‑life induced flies compared with constitutively active InR controls, while early‑life metabolic activity remains unchanged.
3. Reciprocal experiment: constitutive knock‑down of InR extends lifespan but reduces early‑life fecundity; inducible knock‑down limited to late life will rescue fecundity without further extending lifespan, confirming the directionality of the trade‑off.

Mechanistic insight – AP alleles likely evolved because their early‑life signaling boosts growth and reproduction, inadvertently activating downstream stress‑response pathways (FOXO, NF‑κB) that later manifest as SAS

Hypothesis

Aging is driven by a conserved, actively maintained senescence execution program that is suppressed when extrinsic mortality is low and somatic investment yields inclusive‑fitness benefits. The program functions as a conditional switch: under high extrinsic mortality (typical post‑reproductive environments) it promotes timely death to free resources for kin; under low extrinsic mortality it is attenuated, allowing extended somatic maintenance without compromising early‑life fitness.

Mechanistic Basis

• The execution program centers on the mitochondrial permeability transition pore (mPTP) complex, whose opening triggers a cascade of oxidative damage and inflammasome activation that culminates in organismal decline.
• mPTP activity is regulated by the NAD⁺‑dependent deacetylase SIRT3 and by circulating kin‑signaling peptides (e.g., insulin‑like growth factor binding proteins) that rise when population density is high and relatedness is elevated.
• When extrinsic mortality is low, reduced stress signaling lowers cytosolic Ca²⁺ and ROS, keeping mPTP closed; SIRT3 activation further raises the threshold for pore opening. This creates a reversible, physiologically tunable senescence brake.
• The system aligns with antagonistic pleiotropy: alleles that enhance early‑life growth and reproduction modestly increase basal mPTP sensitivity, a cost that is only realized when the environmental cue for low extrinsic mortality is absent.

Testable Predictions

1. In C. elegans, exposure to a pheromone blend that signals high population density will increase mPTP openi

Hypothesis\nAging reduces colonic NAD+ levels, which diminishes tetrahydrobiopterin (BH4) recycling and thereby limits TPH1 activity in enterochromaffin (EC) cells, causing a decline in gut‑derived serotonin that contributes to age‑related motility dysfunction.\n\n## Mechanistic Rationale\n- NAD+ is a cofactor for the salvage pathway that regenerates BH4 from dihydrobiopterin via enzymes such as GTP cyclohydrolase I (GCH1) and sepiapterin reductase; reduced NAD+ lowers NADPH availability, impairing BH4 regeneration.[1]\n- BH4 is an essential cofactor for TPH1; insufficient BH4 shifts TPH1 toward uncoupled activity, producing superoxide instead of serotonin.[2]\n- NAD+‑dependent sirtuins (SIRT1/SIRT2) deacetylate TPH1, enhancing its catalytic efficiency; NAD+ loss leads to hyperacetylation and reduced enzyme activity.[3]\n- EC‑cell mechanosensing via Piezo2 remains intact, but the biochemical capacity to convert tryptophan to 5‑HT is compromised.\n\n## Predictions & Experimental Design\n1. EC‑cell‑specific NAD+ boost – Generate mice with EC‑cell‑targeted expression of NAMPT (using Tph1‑Cre) or administer EC‑cell‑directed NMN nanoparticles. Predict: restored TPH1 activity, normal colonic serotonin levels, and improved colonic transit in aged mice despite unchanged microbiota composition.\n2. NAD+ depletion in young mice – Treat young mice with EC‑cell‑specific NAMPT shRNA or systemic FK866 (NAMPT inhibitor). Predict: rapid decline in EC‑cell serotonin production and motility resembling aged phenotype.\n3. Microbiota independence – Perform the above experiments

Hypothesis

Chronic low‑grade pain acts as a hormetic signal that sustains gut barrier function and microbiota balance through TRPV1‑dependent activation of colonic epithelial AMPK‑SIRT1 signaling; pharmacologic silencing of this signal with NSAIDs removes the cue, leading to decreased butyrate production, increased permeability, and accelerated inflammaging (see NSAID‑induced microbiota shifts and barrier damage)[1].

Mechanistic Rationale

Pain‑sensing neurons in the gut release substance P and calcitonin gene‑related peptide (CGRP) upon mild mechanical or thermal stimulation. These neuropeptides bind receptors on enterochromaffin cells and intestinal epithelial cells, triggering calcium influx that activates the calcium‑calmodulin‑dependent kinase kinase β (CAMKKβ) → AMPK pathway. AMPK activation promotes SIRT1 deacetylase activity, which upregulates tight‑junction protein expression (occludin, claudin‑1) and enhances fatty‑acid oxidation, providing colonocytes with the energy needed to maintain a hypoxic lumen favoring obligate anaerobes such as butyrate‑producing Clostridia. In parallel, TRPV1‑mediated signaling stimulates colonic mucosal release of catecholamines that inhibit growth of facultative anaerobes (Proteobacteria) via α‑adrenergic receptor signaling. Thus, intermittent pain cues create a feedback loop: epithelial health → microbiota composition → reduced luminal irritants → appropriate pain signaling.

When NSAIDs inhibit COX‑derived prostaglandins, they also blunt TRPV1 sensitization (prostaglandins lower the activation threshold of TRPV1)[1]. The resul

Hypothesis

Morning exposure to high‑intensity, blue‑enriched dawn light (>1000 lux, 460‑480 nm) triggers a sustained ipRGC‑mediated activation of the AMPK‑SIRT1‑NAD+ axis, thereby priming cellular antioxidant defenses and mitochondrial respiration that offset the deleterious effects of evening blue‑light exposure on circadian health.

Mechanistic Rationale

1. ipRGC signaling to metabolic hubs – Intrinsically photosensitive retinal ganglion cells project not only to the suprachiasmatic nucleus but also to the intergeniculate leaflet and olivary pretectal nucleus, regions that influence autonomic output to peripheral tissues. Recent work shows that acute ipRGC activation can increase sympathetic tone to brown adipose tissue, raising cAMP and activating AMPK [1].

2. AMPK‑SIRT1‑NAD+ cascade – AMPK phosphorylation stimulates NAD+ biosynthesis via NAMPT, increasing SIRT1 deacetylase activity. SIRT1 then deacetylates PGC‑1α, enhancing mitochondrial biogenesis and upregulating antioxidant enzymes (SOD2, catalase). This creates a “metabolic shield” that reduces ROS accumulation later in the day.

3. Counteracting evening blue light – Evening blue‑light (<10 lux, red‑shifted) suppresses melatonin and elevates intracellular ROS in neurons and hepatocytes, a process linked to amyloid‑β aggregation and insulin resistance [3]. If the morning‑induced AMPK‑SIRT1 axis is alre